Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2026)

Ani Pharmaceuticals' Non-Current Debt history spans 9 years, with the latest figure at $291.8 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 5.59% to $291.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $291.8 million, a 5.59% decrease, with the full-year FY2025 number at $291.8 million, down 5.59% from a year prior.
  • Non-Current Debt hit $291.8 million in Q4 2025 for Ani Pharmaceuticals, down from $297.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for ANIP hit a ceiling of $312.9 million in Q3 2024 and a floor of $169.0 million in Q1 2021.
  • Historically, Non-Current Debt has averaged $275.1 million across 5 years, with a median of $285.8 million in 2022.
  • Biggest five-year swings in Non-Current Debt: decreased 10.16% in 2021 and later surged 69.43% in 2022.
  • Tracing ANIP's Non-Current Debt over 5 years: stood at $286.5 million in 2021, then dropped by 0.3% to $285.7 million in 2022, then dropped by 0.3% to $284.8 million in 2023, then rose by 8.53% to $309.1 million in 2024, then decreased by 5.59% to $291.8 million in 2025.
  • Business Quant data shows Non-Current Debt for ANIP at $291.8 million in Q4 2025, $297.7 million in Q3 2025, and $301.5 million in Q2 2025.